Francucci C M, Daniele P, Iori N, Camilletti A, Massi F, Boscaro M
Division of Endocrinology, Department of Internal Medicine, University of Ancona, Italy.
J Endocrinol Invest. 2005 Jul-Aug;28(7):623-31. doi: 10.1007/BF03347261.
The aim of our prospective, randomised, controlled and open-label clinical study was to evaluate in healthy post-menopausal women the effects of raloxifene (RLX) on body fat distribution and lipids, and the correlations between these parameters. The fat distribution, by dual energy X-ray absorptiometry, and lipids were evaluated at baseline and after 1 yr in 50 post-menopausal women: 25 were treated with RLX 60 mg/die, while 25 served as control group (CG). After 1 yr, we observed in RLX-users a slight reduction of fat mass in trunk and central region and an increase in legs and, in relation to CG, significantly lower values of adiposity in trunk and abdominal region (p < 0.05). At the same time, HDL-cholesterol (HDL-C) and apolipoprotein A1 (ApoA1) were significantly increased in relation to baseline values and CG (p < 0.05) and apolipoprotein B (ApoB), total cholesterol/HDL-C, LDL cholesterol/ HDL-C, and ApoB/ApoA1 ratios significantly decreased compared to baseline values and CG (p < 0.05). No correlation was underlined among lipids and regional fat distribution. These results highlight the positive effect of RLX on lipids and suggest, for the first time, that RLX promotes the shift from android to gynoid fat distribution, and prevents the uptrend of abdominal adiposity and body weight compared with untreated women.
我们这项前瞻性、随机、对照、开放标签的临床研究旨在评估雷洛昔芬（RLX）对健康绝经后女性身体脂肪分布和血脂的影响，以及这些参数之间的相关性。采用双能X线吸收法评估了50名绝经后女性在基线期和1年后的脂肪分布情况，并检测了血脂水平：其中25名女性接受60mg/d的RLX治疗，另外25名作为对照组（CG）。1年后，我们观察到服用RLX的女性躯干和中心区域的脂肪量略有减少，腿部脂肪量增加，并且与CG组相比，躯干和腹部区域的肥胖程度显著降低（p<0.05）。同时，与基线值和CG组相比，高密度脂蛋白胆固醇（HDL-C）和载脂蛋白A1（ApoA1）显著升高（p<0.05），而载脂蛋白B（ApoB）、总胆固醇/HDL-C、低密度脂蛋白胆固醇/HDL-C以及ApoB/ApoA1比值与基线值和CG组相比显著降低（p<0.05）。未发现血脂与局部脂肪分布之间存在相关性。这些结果突出了RLX对血脂的积极作用，并首次表明，与未治疗的女性相比，RLX可促进脂肪分布从男性型向女性型转变，防止腹部肥胖和体重上升。
